These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

818 related items for PubMed ID: 18096270

  • 1. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
    Cole ET, Cadé D, Benameur H.
    Adv Drug Deliv Rev; 2008 Mar 17; 60(6):747-56. PubMed ID: 18096270
    [Abstract] [Full Text] [Related]

  • 2. [A review on liquid-filled hard gelatin capsules].
    Ma JH, Yang M, Zeng M, Chen XM, Lan J.
    Zhongguo Zhong Yao Za Zhi; 2008 Mar 17; 33(5):602-5. PubMed ID: 18536390
    [Abstract] [Full Text] [Related]

  • 3. Investigations into the use of pregelatinised starch to develop powder-filled hard capsules.
    Gohil UC, Podczeck F, Turnbull N.
    Int J Pharm; 2004 Nov 05; 285(1-2):51-63. PubMed ID: 15488679
    [Abstract] [Full Text] [Related]

  • 4. Rheology and filling characteristics of particulate dispersions in polymer melt formulations for liquid fill hard gelatin capsules.
    Rowley G, Hawley AR, Dobson CL, Chatham S.
    Drug Dev Ind Pharm; 1998 Jul 05; 24(7):605-11. PubMed ID: 9876504
    [Abstract] [Full Text] [Related]

  • 5. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design.
    Vandecruys R, Peeters J, Verreck G, Brewster ME.
    Int J Pharm; 2007 Sep 05; 342(1-2):168-75. PubMed ID: 17573214
    [Abstract] [Full Text] [Related]

  • 6. Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects.
    Wang CY, Ho HO, Lin LH, Lin YK, Sheu MT.
    Int J Pharm; 2005 Jun 13; 297(1-2):89-97. PubMed ID: 15885936
    [Abstract] [Full Text] [Related]

  • 7. Approaches for the development of solid and semi-solid lipid-based formulations.
    Jannin V, Musakhanian J, Marchaud D.
    Adv Drug Deliv Rev; 2008 Mar 17; 60(6):734-46. PubMed ID: 18045728
    [Abstract] [Full Text] [Related]

  • 8. Performance qualification of a new hypromellose capsule: part I. Comparative evaluation of physical, mechanical and processability quality attributes of Vcaps Plus, Quali-V and gelatin capsules.
    Sherry Ku M, Li W, Dulin W, Donahue F, Cade D, Benameur H, Hutchison K.
    Int J Pharm; 2010 Feb 15; 386(1-2):30-41. PubMed ID: 19900518
    [Abstract] [Full Text] [Related]

  • 9. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG, Law D, Schmitt EA, Qiu Y.
    Adv Drug Deliv Rev; 2004 Feb 23; 56(3):371-90. PubMed ID: 14962587
    [Abstract] [Full Text] [Related]

  • 10. Modulating drug release profiles by lipid semi solid matrix formulations for BCS class II drug--an in vitro and an in vivo study.
    M K, Sistla R, Shastri NR.
    Drug Deliv; 2015 May 23; 22(3):418-26. PubMed ID: 24471823
    [Abstract] [Full Text] [Related]

  • 11. Preparation and characterization of novel fast disintegrating capsules (Fastcaps) for administration in the oral cavity.
    Ciper M, Bodmeier R.
    Int J Pharm; 2005 Oct 13; 303(1-2):62-71. PubMed ID: 16111845
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In-line ATR-UV and Raman Spectroscopy for Monitoring API Dissolution Process During Liquid-Filled Soft-Gelatin Capsule Manufacturing.
    Wan B, Zordan CA, Lu X, McGeorge G.
    AAPS PharmSciTech; 2016 Oct 13; 17(5):1173-81. PubMed ID: 26604007
    [Abstract] [Full Text] [Related]

  • 14. Bio-relevant dissolution testing of hard capsules prepared from different shell materials using the dynamic open flow through test apparatus.
    Garbacz G, Cadé D, Benameur H, Weitschies W.
    Eur J Pharm Sci; 2014 Jun 16; 57():264-72. PubMed ID: 24021609
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance.
    Schamp K, Schreder SA, Dressman J.
    Eur J Pharm Biopharm; 2006 Apr 16; 62(3):227-34. PubMed ID: 16246538
    [Abstract] [Full Text] [Related]

  • 17. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M, Nick S, Parrott N, Röthlisberger D.
    Eur J Pharm Sci; 2006 Jan 16; 27(1):91-9. PubMed ID: 16219449
    [Abstract] [Full Text] [Related]

  • 18. Effect of glycine/citric acid on the dissolution stability of hard gelatin capsules.
    Adesunloye TA, Stach PE.
    Drug Dev Ind Pharm; 1998 Jun 16; 24(6):493-500. PubMed ID: 9876614
    [Abstract] [Full Text] [Related]

  • 19. Cyclodextrins in drug delivery.
    Loftsson T, Jarho P, Másson M, Järvinen T.
    Expert Opin Drug Deliv; 2005 Mar 16; 2(2):335-51. PubMed ID: 16296758
    [Abstract] [Full Text] [Related]

  • 20. Developing early formulations: practice and perspective.
    Li P, Zhao L.
    Int J Pharm; 2007 Aug 16; 341(1-2):1-19. PubMed ID: 17658228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.